Financial Data and Key Metrics Changes - Revenue for the year was $75 million, a significant increase from approximately $29 million in 2024, with $36 million stemming from settling patent infringement claims against Bruker [13][14] - The net loss for the year was roughly $146 million, an improvement compared to a loss of about $163 million in the previous year, resulting in a loss of $0.49 per share [14] - Operating activities used approximately $130 million in cash and equivalents for the year [14][16] Business Line Data and Key Metrics Changes - The company initiated work on one additional partner-initiated program, bringing the cumulative total to 104 programs with downstream participation [10] - The focus on proprietary pipeline advancement led to a decision to stop reporting on partner-initiated program starts on a quarterly basis starting in 2026 [10] Market Data and Key Metrics Changes - The company has approximately $700 million in available liquidity, including $560 million in cash and equivalents and $140 million in committed government funding [10][16] - The clinical pipeline includes 19 molecules that have reached the clinic, with ABCL635 advancing into a Phase 2 study [11][12] Company Strategy and Development Direction - The company aims to become a vertically integrated clinical-stage biotech, having successfully transitioned from building its platform to focusing on pipeline development [4][5] - Key priorities for 2026 include delivering top-line readouts for ABCL635 Phase 2 and ABCL575 Phase 1 studies, advancing ABCL688 and ABCL386 through IND-enabling activities, and adding one new development candidate [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ABCL635, with a positive Phase 2 readout expected to lead to late-stage development [8][9] - The company acknowledges the uncertainties in drug development but remains committed to advancing its pipeline and believes it has sufficient liquidity to fund operations beyond the next three years [17] Other Important Information - The company has made significant investments in property, plant, and equipment to establish clinical manufacturing capabilities, which are now substantially complete [15] - The clinical manufacturing facility allows for better control of the supply chain and improved flexibility [15] Q&A Session Summary Question: Potential for ABCL575 as a combination regimen - Management believes in the potential of OX40 ligand as a class and is exploring combination opportunities internally and with external parties [21][22] Question: Oncology-based BMS studies - Management sees opportunities in breast and prostate cancer, particularly for patients experiencing severe hot flashes [26] - Differentiation in safety and convenience is viewed as a major factor in the product profile [27] Question: Update on ABCL635 target engagement data - The Phase I portion of the study will be released alongside the Phase II data in Q3, with no announcements expected before then [32] Question: Clinical trial infrastructure capacity - The company has reshaped its internal resources to support multiple programs in clinical development and is committed to building operational capacity [43][44] Question: Decision factors for ABCL575 development - The decision will largely depend on external factors, including partnership opportunities and the competitive landscape [45]

Core Viewpoint - The announcement by Heptares Therapeutics regarding its subsidiary Nona Biosciences entering a non-exclusive licensing agreement with Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Nona Biosciences grants Pfizer global rights to utilize its proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Biosciences will receive an upfront payment and is entitled to regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Biosciences to leverage its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

Core Viewpoint - The announcement highlights a strategic partnership between the company’s subsidiary, Nona Bio, and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Nona Bio has entered into a non-exclusive licensing agreement with Pfizer, granting Pfizer global rights to utilize Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Bio will receive an upfront payment and is entitled to receive regulatory, clinical, and commercial milestone payments as part of the agreement [1] Group 2: Collaboration Aspects - The collaboration allows Nona Bio to work with Pfizer, leveraging its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

Core Viewpoint - The announcement highlights a non-exclusive licensing agreement between Nona Bio, a wholly-owned subsidiary of HAPO (02142), and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Pfizer will gain global rights to utilize Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Bio will receive an upfront payment and is entitled to regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Bio to leverage its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） 根據協議條款，輝瑞將獲得諾納生物專有HCAb平台的全球使用權，以開發全人 源僅重鏈抗體。諾納生物將獲得首付款，並有權獲得監管、臨床及商業里程碑付 款。此外，諾納生物可與輝瑞合作，利用諾納生物的HCAb平台、先進的B細胞篩 選技術及綜合服務開展抗體發現、開發及工程。 警示聲明 我們無法保證我們或合作夥伴將能成功開發或最終銷售本公告所提述的任何候選 產品。本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 和鉑醫藥控股有限公司 主席兼執行董事 王勁松博士 （股份代號：02142） 自願公告 與輝瑞訂立非獨家授權協議 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 本公司董事會（「董事會」）欣然宣佈，本公司 ...